CTLA4 and metastatic melanoma: Another retrospective cohort study including patients diagnosed with metastatic melanoma and treated with anti-PD-1 only or anti-CTLA4/anti-PD-1 combination therapies, with or without metformin, suggested favorable treatment-related outcomes including OS and PFS in patients who have received metformin in combination with immune CPI [158].